Bruker Corporation
BRKR
$34.29
-5.43%
Bruker Corporation is a global manufacturer of high-performance scientific instruments and diagnostic tests, serving customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates as a specialized technology leader, focusing on analytical and diagnostic solutions across its four main segments: BioSpin, CALID, Nano, and Energy & Supercon Technologies, with its CALID segment being the primary revenue driver. The current investor narrative centers on navigating a challenging demand environment, as evidenced by recent quarterly revenue stagnation and a significant stock price decline from its highs, raising questions about the company's near-term growth trajectory and margin resilience amidst broader market pressures.…
BRKR
Bruker Corporation
$34.29
BRKR 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Bruker Corporation's 12-month outlook, with a consensus price target around $44.58 and implied upside of +30.0% versus the current price.
Average Target
$44.58
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$27 - $45
Analyst target range
Analyst coverage for BRKR appears limited with only 3 analysts providing estimates for revenue and EPS, and the institutional ratings data shows a mixed but leaning positive sentiment with recent actions including Guggenheim and BofA Securities maintaining 'Buy' ratings, Barclays at 'Overweight', while Goldman Sachs has a 'Sell' and TD Cowen and Citigroup are at 'Hold' or 'Neutral'. The average revenue estimate for the period is $4.24 billion with an EPS estimate of $3.40, but a consensus price target is not provided in the data, making it impossible to calculate a specific implied upside or downside from the current price of $40.70. The target price range is also unavailable, and while the recent ratings show no dramatic changes (mostly reiterations), the limited number of covering analysts and the wide dispersion in recommendations (Buy to Sell) signals higher-than-average uncertainty and a lack of strong conviction on the stock's near-term direction.
Bulls vs Bears: BRKR Investment Factors
The evidence is finely balanced but tilts bearish in the near term due to fundamental deterioration in revenue growth and profitability. The bull case rests almost entirely on a deep valuation discount and expectations for a cyclical recovery, while the bear case is supported by concrete, recent operational weakness. The single most important tension in the investment debate is whether BRKR's current challenges are a temporary cyclical downturn in its end-markets (justifying the value play) or a sign of deeper competitive or structural issues (validating the bearish multiple compression). The resolution of this question hinges on the company demonstrating a return to consistent, positive revenue growth in upcoming quarters.
Bullish
- Deep Value on Historical PS: BRKR trades at a trailing PS ratio of 2.08x, a steep discount to its own historical range which has been as high as 20.14x and was at 7.33x as recently as Q4 2025. This suggests the market has priced in extreme pessimism, creating a potential re-rating opportunity if fundamentals stabilize.
- Stable Gross Margin Profile: The company maintains a robust gross margin, with the most recent quarter at 47.77% and a trailing figure of 45.61%. This indicates pricing power and operational efficiency in its core instrument business, providing a buffer against top-line volatility.
- Strong Balance Sheet & Liquidity: With a debt-to-equity ratio of 0.83 and a current ratio of 1.73, BRKR's financial leverage is moderate and liquidity is healthy. This provides flexibility to navigate a demand slowdown without a liquidity crisis.
- Analyst EPS Growth Forecast: Analysts forecast an average EPS of $3.40 for the coming period, implying a significant recovery from the marginally negative trailing EPS. This forward PE of ~16.9x suggests expectations for a return to profitability and earnings growth.
Bearish
- Stagnant & Volatile Revenue Growth: Q4 2025 revenue of $977.2M declined -0.24% YoY, and quarterly revenues have been volatile ($860.5M, $797.4M, $801.4M in prior quarters). This lack of consistent top-line momentum undermines the growth narrative and pressures valuation multiples.
- Inconsistent Profitability & Negative ROE: Trailing net margin is -0.25% and ROE is -0.35%, indicating the company is not generating shareholder returns. Quarterly results swing dramatically, from a $26M profit in Q4 to a -$59.6M loss in Q3, highlighting operational instability.
- High Valuation on Cash Flow & EBITDA: The stock trades at a high Price-to-Cash-Flow ratio of 53.3x and an EV/EBITDA of 30.9x. These elevated multiples are difficult to justify given the current lack of earnings growth and modest TTM free cash flow of $43.3M.
- Negative Momentum vs. Market: BRKR has significantly underperformed the market, with a -18.6% relative strength over 3 months and -22.7% over 1 year versus the S&P 500. Its beta of 1.2 means it is 20% more volatile, amplifying downside during market stress.
BRKR Technical Analysis
The stock is in a pronounced downtrend from its 52-week highs, with a 1-year price change of +12.18% masking a severe recent correction; the current price of $40.70 sits at just 42% of its 52-week range ($28.53 to $56.22), indicating it is trading much closer to its lows than its highs, which may signal a deep value opportunity but also reflects substantial negative momentum and investor pessimism. Recent momentum is sharply negative and diverges from the longer-term positive 1-year return, with the stock down -15.89% over the past 3 months and a 1-month surge of +19.60% representing a volatile rebound from oversold conditions, as evidenced by the price collapsing to a low of $32.76 in mid-March before the recent rally. Key technical support is firmly established at the 52-week low of $28.53, while resistance looms at the 52-week high of $56.22; a sustained move above the recent rebound highs near $40 would be needed to signal a potential trend reversal, while the stock's beta of 1.201 indicates it is approximately 20% more volatile than the broader market, which amplifies both downside risk and potential upside during recoveries.
Beta
1.20
1.20x market volatility
Max Drawdown
-39.9%
Largest decline past year
52-Week Range
$29-$56
Price range past year
Annual Return
-13.9%
Cumulative gain past year
| Period | BRKR Return | S&P 500 |
|---|---|---|
| 1m | -0.1% | +12.6% |
| 3m | -22.5% | +2.5% |
| 6m | -11.9% | +4.3% |
| 1y | -13.9% | +28.4% |
| ytd | -28.7% | +4.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BRKR Fundamental Analysis
Revenue growth has stagnated and turned slightly negative, with Q4 2025 revenue of $977.2 million representing a -0.24% year-over-year decline, and the multi-quarter trend shows volatility with revenues of $860.5M in Q3, $797.4M in Q2, and $801.4M in Q1, indicating a lack of consistent top-line momentum which pressures the growth investment case. Profitability is inconsistent with a net margin of -0.25% on a trailing basis, though the most recent quarter showed a return to profitability with net income of $26 million and a gross margin of 47.77%, which is stable compared to the 45.61% trailing gross margin; however, quarterly results have swung from a net loss of -$59.6 million in Q3 to the recent profit, highlighting operational volatility. The balance sheet shows moderate leverage with a debt-to-equity ratio of 0.83 and a healthy current ratio of 1.73, while free cash flow generation is positive but modest at $43.3 million TTM, and an ROE of -0.35% indicates the company is not currently generating shareholder returns from its equity base, suggesting financial health is adequate but not robust enough to drive significant self-funded growth.
Quarterly Revenue
$977200000.0B
2025-12
Revenue YoY Growth
+0.00%
YoY Comparison
Gross Margin
+0.47%
Latest Quarter
Free Cash Flow
$43300000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BRKR Overvalued?
Given the trailing net income is marginally negative at -$0.0012 per share, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The stock trades at a trailing PS of 2.08x and a forward PS implied by analyst revenue estimates is approximately 1.69x (market cap $7.15B / estimated revenue $4.24B), with the gap suggesting the market anticipates modest sales growth ahead. Compared to industry averages, specific peer multiples are not provided in the data, but the EV/Sales ratio of 2.25x offers another sales-based valuation point; without a direct industry benchmark, the justification for any premium or discount cannot be quantified from the given data. Historically, the current PS ratio of 2.08x is significantly below its own historical range observed in the data, which has seen PS ratios as high as 20.14x in mid-2021 and was at 7.33x as recently as Q4 2025; trading near the bottom of its historical band suggests the market is pricing in substantial pessimism or anticipating fundamental deterioration, presenting a potential value scenario if operations stabilize.
PE
-831.5x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -21x~302x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
30.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on inconsistent profitability and weak cash generation. The trailing net margin of -0.25% and an ROE of -0.35% show the company is struggling to translate revenue into shareholder returns. Quarterly net income has swung from a $26M profit to a -$59.6M loss, indicating high operational volatility. While free cash flow is positive at $43.3M TTM, the P/CF ratio of 53.3x is exorbitant, suggesting cash flow is insufficient to support the current valuation without significant acceleration.
Market & Competitive Risks are heightened by valuation compression and poor relative performance. Trading at an EV/EBITDA of 30.9x, BRKR carries a high multiple that is vulnerable if growth fails to materialize. The stock's beta of 1.201 means it is 20% more volatile than the market, which has contributed to its severe underperformance (-22.7% relative strength over 1 year). In the competitive medical devices sector, stagnation in the core CALID segment revenue could signal market share loss or pricing pressure, though specific peer data is unavailable for direct comparison.
Worst-Case Scenario involves a continuation of the revenue decline and margin pressure, triggering further multiple compression towards its historical lows. If the company fails to meet the analyst EPS forecast of $3.40 and instead reports further losses, the stock could re-test its 52-week low of $28.53. From the current price of $40.70, this represents a potential downside of approximately -30%. A chain of events including a Q1 2026 earnings miss, guidance reduction, and analyst downgrades could catalyze this move, especially given the stock's high volatility.